Sector News

Celladon halves its workforce to conserve cash after gene therapy meltdown

May 15, 2015
Life sciences
Reeling after the Phase IIb failure of its “breakthrough” gene therapy for heart failure, Celladon ($CLDN) is slashing its budget and payroll, vowing to find a way forward that preserves value for its investors.
 
Last month, the company disclosed that its top prospect, Mydicar, failed to reduce hospitalizations, improve cardio survival rates or free patients from the need for ventricular-assist devices and heart transplants, an across-the-board failure that decimated the company’s market value.
 
Now the San Diego biotech is scrimping to stay alive, reducing its 34-person staff by 50% this quarter in an effort to save cash. Celladon is also backing out of a pair of manufacturing agreements with Novasep and Lonza–no longer needed now that Mydicar isn’t headed for Phase III–and the company is walking away from a loan agreement under which it would have taken on $15 million in debt.
 
Celladon closed the quarter with $70.6 million in cash and equivalents, enough to keep the doors open as management evaluates its pipeline and looks into “strategic alternatives to maximize value for our stockholders,” the company said in a regulatory filing. The company has already nixed an ongoing Phase I trial testing Mydicar in conjunction with a heart device and is now weighing what to do with a preclinical stem cell program to treat heart attack and an early-stage small-molecule drug with the same target as Mydicar.
 
“We are in the process of conducting an extensive review of the (Mydicar) data in the attempt to better understand the observed negative outcome,” CEO Krisztina Zsebo said in a statement. “Meanwhile, we are conserving our cash resources and are assessing our other previously planned clinical trials and development programs. We are also evaluating our strategic options in order to determine the best path forward to maximize shareholder value.”
 
To Celladon’s credit, throughout the Mydicar debacle, management has been up front with the public, bucking a trend in biotech and declining to mine for positive results in its failed trial or spin the setback as a success.
 
By Damian Garde
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.